Research Analysts Issue Forecasts for INO Q1 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Analysts at HC Wainwright raised their Q1 2025 earnings estimates for Inovio Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.75) per share for the quarter, up from their previous estimate of ($0.78). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million.

INO has been the subject of several other reports. Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, StockNews.com raised shares of Inovio Pharmaceuticals to a “sell” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $12.20.

Inovio Pharmaceuticals Trading Down 1.0 %

NASDAQ:INO opened at $1.92 on Friday. Inovio Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $14.75. The stock has a 50-day moving average price of $2.04 and a two-hundred day moving average price of $3.69. The stock has a market cap of $50.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.92.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Alpine Global Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets grew its position in Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 3,630 shares in the last quarter. Bank of Montreal Can acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $43,000. Boothbay Fund Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $44,000. Finally, Barclays PLC lifted its position in Inovio Pharmaceuticals by 15.0% during the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 5,111 shares in the last quarter. Institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.